|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 13, Num. 1, 2008, pp. 52-56
|
Middle East Fertility Society Journal, Vol.
13, No. 1, 2008, pp. 52-56
A randomized trial of letrazole versus clomiphene
citrate in induction of ovulation in patients with polycystic ovary syndrome
(PCOS)
Adel F. El Bigawy, M.D., Usama M. F. Fouda, M.D., Hala A.E. Wahab, M.D.
Department of Obstetrics and Gynecology, Cairo
university, Cairo, Egypt
Correspondence: Adel Farouk, M.D., 25A El Dokki street, E-mail: adel_farouk1@yahoo.com
Received
on August 13, 2007; revised and accepted on September 2, 2007
Code Number: mf08011
ABSTRACT
Objective: The aim of this study was to compare the
effect of letrazole (2.5mg) and clomiphene citrate (150mg) on ovulation in
patients with polycystic ovary syndrome.
Design: Prospective randomized trial.
Setting: University teaching hospital.
Materials and Methods: Sixty four consecutive patients with
polycystic ovary syndrome were recruited. Thirty four patients (70 cycles) were
given clomiphene citrate and thirty patients (64 cycles) were given letrazole.
Both drugs were given orally on days 3-7 of menses. Letrazole, clomiphene
citrate, ovulation induction, timed intercourse.
Main outcome measures: Number of follicles, endometrial
thickness and pregnancy rates.
Results: The mean age, body mass index, and
duration of infertility in both groups were similar. Ovulation occurred in 78%
of the cycles (50 /64) in letrazole treated group and 73% of the cycles (51/70)
in clomiphene citrate treaded group. The endometrial thickness was
significantly higher in letrazole group, the number of mature follicles was
significantly lower in the letrazole group. Pregnancy rate per cycle was 16% in
the letrazole group and 13% in the clomiphene citrate group.
Conclusion: Aromatase inhibitor letrazole is as
effective as clomiphene citrate in induction of ovulation in patients with
polycystic ovarian syndrome, and may have a role as first line treatment for
anovulatory patients with polycystic ovary syndrome.
Key words: letrozole, clomiphene citrate,
polycystic ovary, ovulation, conception
Polycystic ovary
syndrome is an extremely common disorder affecting 4% to 12% of women of
reproductive age (1). For more than 4 decades, clomiphene citrate has been the
main drug used in treatment of patients with polycystic ovary syndrome (2). Although
clomiphene citrate is easy to use and results in ovulation in most patients
with polycystic ovary syndrome, but pregnancy rates were disappointing. This
has been attributed to its peripheral
antiestrogenic effect on endometrium and cervical mucous (3). Recently, Mitwally
and Casper published some data showing the success of the aromatase inhibitor (letrazole)
in anovulatory women resistant to clomiphene citrate, women with unexplained
infertility, and in addition with FSH to improve the ovarian response in poor
responders (4, 5).The aim of this prospective randomized study is to determine
whether letrazole can be used as an alternative to clomiphene citrate in
induction of ovulation in patients with polycystic ovary syndrome.
Table 1. Characteristics of
patients undergoing ovulation with letrazole and with clomiphene citrate
|
Clomiphene citrate
(70 cycles)
|
Letrazole
(64 cycles)
|
P value
|
|
|
|
|
Age (years)
|
27.41±3.7
|
26.33±3.72
|
0.250
|
Mean infertility period (years)
|
3.12±1.66
|
2.87±1.8
|
0.565
|
Body mass index (kg/m2)
|
32.16±4.18
|
31.26±4.2
|
0.394
|
Variables are given as mean ±SD
NS= not significant
MATERIAL AND METHODS
This prospective
randomized trial was performed in Cairo university hospitals, Cairo, Egypt. Sixty four patients with polycystic ovary syndrome according to the Rotterdam revised
criteria for polycystic ovary syndrome were included in the study (6), all
patients had a history of oligomenorrhea or amenorrhea and ovaries with at
least 12 subcapsular cysts 2-9mm in diameter and increased ovarian volume
(>10 ml). Our inclusion criteria were age (18-37) years, period of
infertility > 1 year, day 3 serum level of FSH < 12 IU/L, and serum prolactin
level within normal limits in early follicular phase. Exclusion criteria were
history of pelvic surgery or infertility factors other than anovulation.
The study protocol was
approved by the hospital research ethics board. Study participants were counseled,
and informed consent was taken before randomization. Patients were randomized
to clomiphene citrate (n = 34) or letrazole (n = 30), a quasi-randomization
method was used. Based on the attendance order, patients with odd numbers were
prescribed letrazole and those with even numbers were given clomiphene citrate.
Neither the patients nor the doctors were blinded in any of the groups.
Letrazole (Femara; Novertis pharma AG, Basle, Switzerland) and Clomiphene
citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo,
Egypt) were given orally in doses of 2.5mg/day and 150mg/day respectively for
five days beginning on day 3 of menstrual cycle. Transvaginal ultrasound (siemens,
sonoline, prima) was performed on day 3 of the menstrual cycle before starting
treatment, follicular development was monitored using transvaginal ultrasound
from day 10 of the cycle.
Human chorionic
gonadotropin (Pregnyl ;N.V. Organon, Oss, Holland) at dose of 10.000 IU was
used to trigger ovulation when at least one follicle exceeding 18mm was noted. Endometrial
thickness was assessed according to the method described by Goren and Casper
(7), the endometrial thickness was measured at the greatest diameter
perpendicular to the midsagittal plane in the fundal region, including both
layers of the endometrial cavity, the image was oriented so that the
endometrial canal and the cervical canal were visualized in the same plane to
ensure measurement through the center of the endometrium. Pregnancy was
diagnosed by b-subunit HCG performed 2
weeks from timed intercourse, and ultrasound was performed 2 - 4 weeks after a
positive pregnancy test to confirm clinical pregnancy.
Statistical methods
Data were
statistically described in terms of mean ± standard deviation (± SD),
frequencies (number of cases) and relative frequencies (percentages) when
appropriate. Comparison of quantitative variables between the study groups was
done using Student t test for independent samples. For comparing categorical
data, Chi square (X2) test was performed. Yates correction
was used in stead when the expected frequency is less than 5. A probability
value (p value) less than 0.05 was considered statistically significant. All
statistical calculations were done using computer programs Microsoft Excel version
7 (Microsoft Corporation, NY, USA) and SPSS (Statistical Package for the Social Science; SPSS Inc.,
Chicago, IL, USA) statistical program.
Table 2. Induction of ovulation
with letrazole and clomiphene citrate
|
Clomiphene citrate
(70 cycles)
|
Letrazole
(64 cycles)
|
P value
|
|
|
|
|
Day of HCG administration
|
12.73±0.93
|
13.06±0.89
|
0.072
|
Endometrial thickness(mm)
|
6.43±1.85
|
9.44±1.81
|
< 0.001
|
Ovulation rate per cycle
|
(51/70)(72.85%)
|
(50/64)(78.12%)
|
0.613
|
Number
of follicles more than 18mm on the day of HCG administration
|
2.49±1.21
|
1.3±0.54
|
< 0.001
|
Pregnancy rate per cycle
|
(9/70)(12.85%)
|
(10/64)(15.62%)
|
0.833
|
Pregnancy rate per cycle and ovulation rate are
expressed as N (%), all other values are given as mean ±SD
HCG : human chorionic gonadotrophin
RESULTS
The mean age, body mass
index, and duration of infertility in both groups were similar (Table 1). The
duration to reach dominant was 13.06±0.89 days in the letrazole group and
12.73±0.93 days in the clomiphene citrate group. Ovulation occurred in 78.12%
of the cycles (50 /64) in letrazole treated group and 72.85% of the cycles
(51/70) in clomiphene citrate treaded group. The endometrial thickness was
significantly higher in letrazole group. In the clomiphene citrate group the
endometrial thickness on the day of HCG administration was more than 5 mm in 60
cycles and less than 5mm in 10 cycles, pregnancy did not occur in any of these
ten cycles, the endometrial thickness was more than 5 mm in all cycles with
letrazole. The number of mature follicles was significantly lower in the
letrazole group. Pregnancy rate per cycle was 15.62% in the letrazole group and
12.85 % in the clomiphene citrate group (Table 2).One case of twin pregnancy
occurred in clomiphene citrate group. One case of abortion occurred in each
group, ectopic pregnancy did not occur in any group.
DISCUSSION
Clomiphene citrate
is the most commonly prescribed medication for ovulation induction in patients
with polycystic ovary syndrome (2). Clomiphene citrate initiates or augments
ovulation by binding to estrogen receptors throughout the body due to
structural similarity to estrogen, clomiphene citrate binding to estrogen
receptors occurs for prolonged periods i.e. weeks rather than hours as with
natural estrogen. This extended binding ultimately depletes estrogen receptors
concentrations by interfering with the normal process estrogen receptors
replenishment (8). Depletion of hypothalamic receptors prevent correct
interpretation of circulating estrogen levels, estrogen concentration was
falsely perceived as low leading to reduced estrogen negative feedback on GnRH
production and subsequent increased gonadotropin (FSH and LH). The rise of FSH
promotes the growth of ovarian follicles and ovulation in anovulatory women
(9). Ovulation is restored in 70 % 80 % but will lead to pregnancy in only
about 30 % - 40 % (10). Peripheral antiestrogenic effect of clomiphene citrate
on the endometrium and cervix are frequently suggested as the possible
explanation of such discrepancy, in addition the accumulation of the isomers of
clomiphene citrate (zu-clomiphene) in the body due to its long half life
(several days to weeks) add to persistence of this antiestrogenic effect
(11).While depression of cervical mucous, occur in about 15% of patients, may be
overcome by intrauterine insemination, suppression of the endometrial
proliferation, unrelated to dose or duration of treatment but apparently
idiopathic (12). Prolonged endometrial estrogen receptor depletion results in
significant thinning of the endometrium. Compared with natural cycles, this
endometrial thinning has been observed in 15% to 50% on clomiphene citrate
(13). Gonen and Casper reported no pregnancies occurring in cycles with
endometrial thickness < 6mm at midcycle and a significantly higher rate of
biochemical pregnancy when the endometrial thickness was 6-8 mm (7).
Letrazole is a third
generation non steroidal aromatase inhibitor licensed for treatment of breast
cancer. Letrazole exerts its function through binding to the hemomoiety of the aromatase
enzyme, which is a member of the cytochrome P450 hemoprotein containing enzyme
complex superfamily that catalyze the rate limiting step in the production of
estrogen, that is, the conversion of androstendione and testosterone via three
hydroxylation steps to estrone and estradiol respectively (14).
The proposed mechanisms
of ovarian stimulation by letrazole are a central effect on releasing the
pituitary-hypothalamic axis from estrogenic negative feedback, therefore
increases gonadotropin secretion and resulting ovarian follicular development.
This indicates that letrazole lead to the same action of clomiphene citrate
without depletion of estrogen receptors, or antiestrogenic effect on cervical
mucous or endometrium.
In women with polycystic
ovary syndrome, there is relative aromatase deficiency in the ovary, resulting
in increase in the ovarian androgen production (15) which is converted to
estrogen by aromatization in the brain, leading to relative oversuppression of
FSH. Letrazole suppress the estrogen production in both the ovaries and the
brain therefore resulting in increase in FSH release and subsequent follicle
stimulation and ovulation. In addition to the central effect on the
pituitary-hypothalamic axis letrazole acts locally on the ovaries, preventing
the conversion of intraovarian androgens into estrogens, leading to temporary
accumulation of androgens and enhances follicle stimulating hormone receptor
gene expression leading to an increase in the sensitivity of the ovarian
follicles to gonadotropins stimulation (16).
The present
study reveals that the induction of ovulation with letrazole is associated with
limited number of mature follicles compared to clomiphene citrate, because
letrazole doesn't deplete estrogen receptors and have short half (45 hours),
unlike clomiphene citrate, normal negative feedback occurs centrally as the
dominant follicle grows and estrogen levels increase, this results in FSH
suppression and atresia of small follicles, and midcycle mono-ovulation occurs
in most patients (17).The result of the present study highlights the main
advantage of letrazole in induction of ovulation in patients with polycystic
ovary syndrome which is mono-ovulation, patients with polycystic ovary syndrome
are often hyper-responders to gonadotropins and at higher risk for ovarian
hyperstimulation syndrome.
One case of twin
pregnancy occurred in clomiphene citrate group and all the pregnancies in the
letrazole group were singleton, this is attributed to mono-ovulation which
occurred in 70% of patients in letrazole group. Mitwally et al reported that
the use of aromatase inhibitor letrazole is associated with significantly lower
multiple pregnancy rates compared with other methods of ovarian stimulation,
they explained this results by the fact that letrazole induce limited number of
mature follicles compared to other methods of induction of ovulation (18).
Higher endometrial
thickness was reported on the day of HCG administration with the letrazole
group compared with clomiphene citrate, in addition all cycles in the letrazole
group had endometrial thickness more than 5 mm while in clomiphene citrate
group the endometrial thickness was less than 5 mm in ten cycles. This
indicates the adverse effect of clomiphene citrate on the endometrial growth that
is thought to be due to depletion of the endometrial receptors, and indicates
that letrazole has no adverse effect on endometrium (19).These results agrees
with the results of Mitwally and Casper and Atay et al (4) (20). On the other
hand another study revealed that there is no significant difference in
endometrial thickness (21).
Although the pregnancy
rate per cycle was higher in the letrazole group (15.62%) than in clomiphene
citrate group (12.85%), that difference is not statistically significant. In a
prospective randomized study the pregnancy rate per cycle was nearly similar
between two groups of patients with polycystic ovary syndrome treated with
letrazole or clomiphene citrate (22). In contrast to our finding, other
randomized study comparing the use of letrazole or clomiphene citrate in
patients with polycystic ovary syndrome, pregnancy rate per cycle was
significantly higher in patients in letrazole group (21% versus 9.1%) (20).
In summery, this
prospective randomized study has demonstrated the advantages of use of
letrazole in patients with polycystic ovary syndrome, which is mono ovulation
and absence of antiestrogenic effect on endometrium, and higher pregnancy rate
per cycle. These properties make letrazole a viable alternative to clomiphene
citrate in patients with polycystic ovary syndrome.
REFERENCES
- Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W,
Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected
black and white women of the southeastern united states : a prospective study.
J clin Endocrin metabol 1998; 83:3078-3082.
-
Wysowski DE. Use of fertility drugs in
the united states, 1979 through 1991. Fertil Steril 1991; 60: 1096-1098.
-
Sheehan MT. Polycystic Ovarian syndrome : Diagnosis and
management. Clinical medicine and research 2004 ;2 : 13-27.
- Mitwally M, Casper R. Use of aromatase inhibitor for
ovulation induction in patients with an inadequate response to clomiphene
citrate. Fertil Steril 2001; 75: 305 -9.
- Mitwally M, Casper R. Aromatase inhibitor improves
ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril
2002; 74: 776-780.
- The Rotterdam ESHRE/ASRM-sponsored PCOS consensus
workshop group. Revised 2003 consensus on diagnostic criteria and long-term
health risks related to polycystic ovary syndrome(PCOS). Human reproduction
2004; 19: 41-47.
- Gonen Y, Casper RF. Sonographic determination of a
possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod
1990;5: 670-4
- Greenblatt RB, Barfield WE, Jungck EC, Ray AW. Induction
of ovulation with MRL/41. JAMA 1961;178:101-105.
- Kurl RN, Morris ID. Differential depletion of cytoplasmic
high affinity estrogen receptors after the in vivo administration of the
antioestrogens, clomiphene, MER-25 and tamoxifen. Br J Pharmacol 1978 ;62:
487-493.
- Imani B, Eijkemans MJ, Velde ER. A
nomogram to predict the probability of live birth after clomiphene citrate
induction of ovulation in normogonadotropic oligomenorrheic infertility. Fertil
Steril 2002; 77:91-97
- Schmidt GE, Kim MH, Mansour R, Torello L, Friedman Cl.
The effects of enclomiphene and zuclomiphene citrates on the mouse embryos
fertilized in vitro and in vivo. Am J Obstet Gynecol 1986; 154:727-736.
- Homburg R. The management of infertility associated with
polycystic ovary syndrome. Reproductive Biology and Endocrinology 2003;1:109.
- Dickey RP, Olar TT, Taylor SN, Curole DN, Matulich EM.
Relationship of endometrial thickness and pattern to fecundity in ovulation
induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin.
Fertil Steril 1993;59: 756-60.
-
Brueggemeier RW. Aromatase inhibitors : Mechanisms of
steroidal inhibitors. Br Cancer Res Treat 1994; 30:31-42.
- Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA.
Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol
Hum Repro 1998;41:1-8.
-
Casper R, Mitwally M. Aromatase inhibitors for ovulation
induction. The Journal of clinical Endocrinology and metabolism
2006;91:760-771.
-
Begum MR, Quadir E, Begum A, Begum RA, Begum M. Role of
aromatase inhibitor in ovulation induction in patients with poor response to
clomiphene citrate. J Obstet Gynaecol Res 2006; 32(5):502-6.
- Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome
after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet
Gynecol 2005; 192: 381-6.
- Cortinez A, De Carvalho I, Vantman D, Gabler F, Iniguez G,
Vega M. Hormonal profile and endometrial morphology in letrazole-controlled
ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril 2005;
83:110-5.
- Atay V, Cam C, Muhcu M, Cam M, Karateke A. Comparison of
letrazole and clomiphene citrate in women with polycystic ovaries undergoing
ovarian stimulation. The Journal of international medical research 2006;34:
73-76.
- Fisher SA, Reid RL, Van Vugt DA, Casper RF. A randomized
double-blind comparison of the effects of clomiphene citrate and the aromatase
inhibitor letrazole on the ovulatory function in normal women. Fertil Steril
2002; 78:280-5.
- Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an
aromatase inhibitor in patients with polycystic ovary syndrome: a prospective
randomized trial. Fertil Steril. 2006; 86(5):1447-51.
©Copyright 2008 - Middle East Fertility Society
|